Effect of actinomycin D and neoarsphenamine on tumor control and skin tolerance in the rat.
Actinomycin D and neoarsphenamine were tested for their ability to produce therapeutically favorable radiosensitization in the WAG/Rij rat. Acute and late skin reactions and control of the BA1112 rhabdomyosarcoma were examined in drug-treated and untreated animals irradiated in single- and five-fraction schedules. Actinomycin D was found to protect skin and tumors when added 15 minutes before irradiation. Actinomycin D added 2 hours before irradiation in a five-fraction trial produced slight tumor sensitization accompanied by slight skin protection. Neoarsphenamine produced significant tumor sensitization without skin sensitization in one of the single-fraction trials, but had no effect in the five-fraction trials.
D000818:Animals; D001152:Arsenicals / Q000494:pharmacology*; D003609:Dactinomycin / Q000494:pharmacology*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy; D011838:Radiation-Sensitizing Agents; D051381:Rats; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000532:radiotherapy*; D012867:Skin / Q000187:drug effects / Q000528:radiation effects*; D013997:Time Factors
D001152:Arsenicals; D011838:Radiation-Sensitizing Agents; D003609:Dactinomycin